Stratistics MRC에 따르면 세계의 펜 니들 시장은 2025년 24억 8,000만 달러를 차지하며 예측 기간 동안 CAGR 9.0%로 성장하여 2032년에는 45억 4,000만 달러에 달할 것으로 예측되고 있습니다. 다양한 길이와 게이지가 있으며 편안하고 효과적인 주사를 보장합니다.
Ypsomed가 2023년 11월에 발표한 데이터에 따르면, 회사의 펜형 주사제, UnoPen과 YpsoPen 수요는 지난 수년간 대폭 증가해, Uno(현재는 MTD Medical Technology and Devices SpA의 일부) 펜의 판매수는 1억개를 넘어, YpsoPen의 판매수는 1000만 개를 넘었습니다.
재택 건강 관리 도입 증가
고령자 인구 증가와 당뇨병 유병률의 상승에 의해 펜형 주사 바늘을 사용한 인슐린의 자기 투여 수요가 높아지고 있습니다. 또한 기존의 주사기에서 인슐린 펜으로의 전환은 투여 정확도와 사용 편의성을 향상시켜 시장의 성장을 더욱 뒷받침하고 있습니다.
훈련과 의식의 부족
부적절한 취급과 투여 기술은 침침 손상, 감염증, 최적의 혈당 조절의 저하로 이어질 수 있습니다. 펜형 주사기의 아픔이나 불쾌감에 대한 오해가 펜형 주사기의 사용을 멀리하는 환자도 있습니다.
당뇨병 관리에 대한 의식 증가
공중 보건 캠페인과 국제 당뇨병 연합(IDF)과 같은 조직의 이니셔티브는 최신 인슐린 투여법에 대한 인식을 높이고 있습니다. 스마트 인슐린 펜을 포함한 디지털 건강 도구의 통합은 복용량 추적과 알림을 제공하여 당뇨병 관리를 더욱 강화합니다.
바늘 찌르기의 위험
사용한 주사 바늘의 부적절한 폐기와 취급은 우발적인 천자로 이어져 HIV와 간염 등의 혈액 매개 감염의 위험을 높입니다. 따라서, 자원이 적은 환경에서의 채용에는 한계가 있습니다. 또한, 복잡하다고 하는 인식으로부터, 환자가 안전 기구를 사용하고 싶지 않은 것도, 문제를 한층 더 악화시키고 있습니다.
COVID-19의 팬데믹은 펜형 주사침 시장에 다양한 영향을 미치고 공급망의 혼란과 병원 진찰의 감소가 처음에는 성장을 둔화시켰습니다. 통원을 피하기 위해 자기 투여를 선호하고 노출 위험을 줄였습니다. 팬데믹 후에는 만성 질환 관리와 예방 헬스케어의 중시가 계속 시장 확대의 원동력이 되고 있습니다.
예측기간 동안 안전펜 니들 분야가 최대화될 전망
안전 주사 바늘 부문은 건강 관리 환경에서 바늘 찌르기 손상 방지를 촉진하는 엄격한 규제 지침에 따라 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예측됩니다. 헬스케어 종사자와 재택 간병인의 사용자 보호를 강화합니다. 통증이 없는 극세침에의 기호의 고조는 당뇨병 환자의 사이에서의 채용을 한층 더 추진하고 있습니다. 또한, 선진 지역에 있어서의 안전 설계 기기에 대한 상환 정책 증가가 시장 개척을 뒷받침하고 있습니다.
예측 기간 동안 병원 부문의 CAGR이 가장 높을 것으로 예상
예측 기간 동안 당뇨병 관련 입원 환자 수가 증가하고 임상 현장에서 인슐린 펜 사용이 증가함에 따라 병원 부문이 가장 높은 성장률을 보일 것으로 예측됩니다. 또한 병원에서 당뇨병 치료를 표준화하기 위한 정부의 이니셔티브와 가치 기반 건강 관리 동향 증가도 이 분야의 성장에 기여하고 있습니다.
예측 기간 동안 아시아태평양이 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 액세스 개선이 시장 성장을 지원하고 있습니다. 이 지역의 원격 의료 및 재택 건강 서비스의 확대는 펜형 주사 바늘 수요를 더욱 밀어 올리고 있습니다.
예측 기간 동안 북미는 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 증가하고 있기 때문에 이 지역 시장을 독점하고 있습니다. 커넥티드 인슐린 펜이나 AI에 의한 투여량 추적 등의 기술적 진보가 인기를 끌고 있습니다. 또, 당뇨병 연구나 디지털 헬스 솔루션에 대한 투자가 증가하고 있는 것도, 시장의 가속에 기여하고 있습니다.
According to Stratistics MRC, the Global Pen Needles Market is accounted for $2.48 billion in 2025 and is expected to reach $4.54 billion by 2032 growing at a CAGR of 9.0% during the forecast period. Pen needles are small, hollow, and thin needles designed for use with insulin pens or other injectable devices to administer medications, such as insulin, in a precise and controlled manner. They come in various lengths and gauges to suit different patient needs, ensuring comfortable and effective injections. Pen needles are commonly used by individuals with diabetes to manage their condition by delivering insulin subcutaneously. They are also used in the administration of other injectable treatments, offering convenience and reducing the need for syringes.
According to data published by Ypsomed in November 2023, the demand for its pen injections, UnoPen and YpsoPen, increased significantly in the past years, and sales exceeded 100 million units of Uno (now part of MTD Medical Technology and Devices S.p.A.) Pen and 10 million units of YpsoPen.
Rising adoption of home healthcare
The growing elderly population, coupled with the rising prevalence of diabetes, has amplified the demand for self-administration of insulin using pen needles. Advancements in needle design, such as thinner and shorter needles, have improved patient comfort and adherence to insulin therapy. Additionally, the shift from conventional syringes to insulin pens has enhanced dosing accuracy and ease of use, further supporting market growth. Government initiatives promoting home-based care and the expansion of telehealth services have also contributed to this trend.
Lack of training and awareness
Improper handling and administration techniques can lead to needlestick injuries, infections, and suboptimal glycemic control. In developing regions, limited access to diabetes education programs exacerbates this issue, leading to poor adherence to insulin therapy. Additionally, misconceptions about pain and discomfort associated with pen needles discourage some patients from adopting them. Healthcare systems in low-income areas often lack structured training programs for insulin delivery devices. Addressing these educational gaps is crucial to maximizing the potential of pen needles in diabetes management.
Growing awareness of diabetes management
Public health campaigns and initiatives by organizations like the International Diabetes Federation (IDF) are raising awareness about modern insulin administration methods. Technological advancements, such as safety-engineered pen needles, are gaining traction due to their ability to reduce needlestick injuries and improve patient safety. The integration of digital health tools, including smart insulin pens, further enhances diabetes management by tracking doses and providing reminders. Emerging markets with rising diabetes prevalence offer untapped potential for market expansion.
Risk of needlestick injuries
Improper disposal and handling of used needles can lead to accidental punctures, increasing the risk of bloodborne infections such as HIV and hepatitis. Regulatory bodies are enforcing stricter guidelines on needle safety, but compliance varies across regions. The high cost of safety-engineered pen needles also limits their adoption in low-resource settings. Additionally, patient reluctance to use safety mechanisms due to perceived complexity further exacerbates the issue. Addressing these challenges requires continuous innovation in needle design and stronger enforcement of safety protocols.
The COVID-19 pandemic had a mixed impact on the pen needles market, with disruptions in supply chains and reduced hospital visits initially slowing growth. However, the increased focus on home-based diabetes management during lockdowns boosted demand for insulin pens and pen needles. Patients preferred self-administration to avoid frequent hospital visits, reducing exposure risks. Post-pandemic, the emphasis on chronic disease management and preventive healthcare continues to drive market expansion. Manufacturers are now prioritizing resilient supply chains and digital health integration to meet evolving patient needs.
The safety pen needles segment is expected to be the largest during the forecast period
The safety pen needles segment is expected to account for the largest market share during the forecast period, driven by stringent regulatory guidelines promoting needlestick injury prevention in healthcare settings. Innovations such as retractable needles, automatic shielding mechanisms, and passive safety designs enhance user protection, particularly for healthcare workers and home caregivers. The growing preference for painless and ultra-thin needles further boosts adoption among diabetes patients. Additionally, increasing reimbursement policies for safety-engineered devices in developed regions support market expansion.
The hospitals segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the hospitals segment is predicted to witness the highest growth rate attributed to the rising number of diabetes-related hospital admissions and the increasing use of insulin pens in clinical settings. The integration of electronic health records (EHRs) with smart insulin pens enhances medication adherence and monitoring. Furthermore, government initiatives to standardize diabetes care in hospitals and the growing trend of value-based healthcare contribute to segment growth.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by the high and growing prevalence of diabetes in countries like India and China. Increasing healthcare expenditure, government-led diabetes awareness programs, and improving access to insulin delivery devices support market growth. The expansion of telemedicine and home healthcare services in the region further boosts demand for pen needles. Additionally, local manufacturers are introducing cost-effective products, making them accessible to a larger patient population.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure, high adoption of safety pen needles, and strong regulatory support for needlestick injury prevention. The U.S. dominates the regional market due to widespread health insurance coverage for diabetes management devices and increasing patient awareness. Technological advancements, such as connected insulin pens and AI-driven dose tracking, are gaining traction. Additionally, rising investments in diabetes research and digital health solutions contribute to market acceleration.
Key players in the market
Some of the key players in Pen Needles Market include Novo Nordisk, Shanghai United Injection Device Co., Ltd., Becton, Dickinson and Company (BD), Ypsomed AG, Terumo Corporation, Mylan N.V., Medtronic, Owen Mumford, Sun Pharma, Diabetes Care, Roche Holding AG, Eli Lilly and Company, Smiths Medical, Injecto Pharmaceuticals, and Antares Pharma.
In March 2025, Novo Nordisk A/S and United Laboratories International Holdings Limited (TUL) announced that Novo Nordisk and TUL's wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd., have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.
In February 2025, Terumo Vietnam Medical Equipment (Terumo Vietnam) and Daiichi Sankyo Vietnam have signed a Memorandum of Understanding (MoU) to collaborate on advancing cardiovascular expertise in Vietnam. The initiative aims to support healthcare professionals in updating their knowledge and skills in interventional cardiology.